A phase IIa study of cannabidiol for the treatment of Acute Graft versus Host Disease
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Cannabidiol (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors TALENT Biotech
- 21 Jun 2018 According to a Kalytera Therapeutics media release, Dr. Moshe Yeshurun, Kalytera's Chief Medical Officer, was the Principal Investigator for this trial.
- 24 Feb 2017 New trial record
- 22 Feb 2017 Results published in Kalytera Therapeutics a media release.